Julie Kim to Become Takeda's New CEO in June 2026

Christophe Weber, the current CEO of Takeda, has announced his retirement scheduled for June 2026. After more than 12 years in leadership, Weber will be succeeded by Julie Kim, who is presently the president of Takeda's U.S. Business Unit.

Background of the Transition

The Board of Directors of Takeda reached a unanimous decision to appoint Kim following a thorough multi-year succession process. This move is seen as a significant step for the company as it prepares for future challenges and opportunities in the biopharmaceutical industry.

At the upcoming Annual General Shareholders Meeting in June 2026, Kim will be proposed for election to the Board. After his retirement, Weber will no longer hold a Board position.

Christophe Weber's Departure

Masami Iijima, the chair of the Board, praised Weber's tenure, stating, "Under his remarkable leadership, Takeda transformed into a global R&D-driven biopharmaceutical firm with a sustainable business model." Iijima expressed gratitude for Weber's significant contributions and his ongoing support for Kim during the transition period.

Weber mentioned that the timing of his succession is strategic, coinciding with the company’s growth outlook and anticipated product launches slated for late 2026.

Julie Kim’s Qualifications

Julie Kim expressed her honor in being chosen to lead Takeda. She acknowledged the growth and transformation the company has experienced under Weber’s leadership and highlighted her commitment to maintaining Takeda's strong cultural values while driving the company forward. Kim has been with Takeda since 2019 and has extensive experience in various roles across the healthcare sector.

Before her current role, she successfully led the Plasma-Derived Therapies Business Unit and has been instrumental in expanding Takeda's presence in the U.S. market.

About Takeda

Founded over 240 years ago, Takeda is dedicated to improving health and enhancing patient care through innovative treatments across various therapeutic areas. The company's mission is to deliver life-transforming medicines that make a meaningful difference in the lives of patients around the world.

Takeda, CEO, Leadership, Biopharmaceutical, Succession